The contribution of Na V 1.6 to the efficacy of voltage‐gated sodium channel inhibitors in wild type and Na V 1.6 gain‐of‐function (GOF) mouse seizure control
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16481 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von James P Johnson und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada. Hauptthemen laut MEDLINE: NAV1.6 Voltage-Gated Sodium Channel, Seizures, Voltage-Gated Sodium Channel Blockers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xenon Pharmaceuticals Inc..
Abstract (Originalsprache)
Background and Purpose Inhibitors of voltage‐gated sodium channels (Na V s) are important anti‐epileptic drugs, but the contribution of specific channel isoforms is unknown since available inhibitors are non‐selective. We aimed to create novel, isoform selective inhibitors of Na v channels as a means of informing the development of improved antiseizure drugs. Experimental Approach We created a series of compounds with diverse selectivity profiles enabling block of Na V 1.6 alone or together with Na V 1.2. These novel Na V inhibitors were evaluated for their ability to inhibit electrically evoked seizures in mice with a heterozygous gain‐of‐function mutation (N1768D/+) in Scn8a (encoding Na V 1.6) and in wild‐type mice. Key Results Pharmacologic inhibition of Na V 1.6 in Scn8a N1768D /+ mice prevented seizures evoked by a 6‐Hz shock. Inhibitors were also effective in a direct current maximal electroshock seizure assay in wild‐type mice. Na V 1.6 inhibition correlated with efficacy in both models, even without inhibition of other CNS Na V isoforms. Conclusions and Implications Our data suggest Na V 1.6 inhibition is a driver of efficacy for Na V inhibitor anti‐seizure medicines. Sparing the Na V 1.1 channels of inhibitory interneurons did not compromise efficacy. Selective Na V 1.6 inhibitors may provide targeted therapies for human Scn8a developmental and epileptic encephalopathies and improved treatments for idiopathic epilepsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
- Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
- Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
- Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
- Neurocrine Biosciences, San Diego, California, USA.
- Scientific Affairs, Xenon Pharmaceuticals, Inc, Burnaby, British Columbia, Canada.
ORCID-Profile: James P Johnson
Förderung
- Xenon Pharmaceuticals Inc.
Zitieren
APA
Johnson, J. P., Focken, T., Karimi Tari, P., Dube, C., Goodchild, S. J., Andrez, J. C., Bankar, G., Burford, K., Chang, E., Chowdhury, S., Christabel, J., Dean, R., de Boer, G., Dehnhardt, C., Gong, W., Grimwood, M., Hussainkhel, A., Jia, Q., Khakh, K., …, & Empfield, J. R. (2024). The contribution of Na V 1.6 to the efficacy of voltage‐gated sodium channel inhibitors in wild type and Na V 1.6 gain‐of‐function (GOF) mouse seizure control. British Journal of Pharmacology. https://doi.org/10.1111/bph.16481
Vancouver
Johnson JP, Focken T, Karimi Tari P, Dube C, Goodchild SJ, Andrez JC, et al. The contribution of Na V 1.6 to the efficacy of voltage‐gated sodium channel inhibitors in wild type and Na V 1.6 gain‐of‐function (GOF) mouse seizure control. British Journal of Pharmacology. 2024. doi:10.1111/bph.16481
BibTeX
@article{Johnson2024,
author = {Johnson, James P and Focken, Thilo and Karimi Tari, Parisa and Dube, Celine and Goodchild, Samuel J and Andrez, Jean-Christophe and Bankar, Girish and Burford, Kristen and Chang, Elaine and Chowdhury, Sultan and Christabel, Jessica and Dean, Richard and de Boer, Gina and Dehnhardt, Christoph and Gong, Wei and Grimwood, Michael and Hussainkhel, Angela and Jia, Qi and Khakh, Kuldip and Lee, Stephanie and Li, Jenny and Lin, Sophia and Lindgren, Andrea and Lofstrand, Verner and Mezeyova, Janette and Nelkenbrecher, Karen and Shuart, Noah Gregory and Sojo, Luis and Sun, Shaoyi and Waldbrook, Matthew and Wesolowski, Steven and Wilson, Michael and Xie, Zhiwei and Zenova, Alla and Zhang, Wei and Scott, Fiona L and Cutts, Alison J and Sherrington, Robin P and Winquist, Raymond and Cohen, Charles J and Empfield, James R},
title = {The contribution of Na V 1.6 to the efficacy of voltage‐gated sodium channel inhibitors in wild type and Na V 1.6 gain‐of‐function (GOF) mouse seizure control},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16481}
}
EUVIMED